Longeveron Cellular Therapy Granted International Non-Proprietary Name
MT Newswires Live
Feb 18
Longeveron (LGVN) said Tuesday that the World Health Organization approved laromestrocel for the non-proprietary name of the company's Lomecel-B cellular therapy.
The US Food and Drug Administration granted Lomecel-B regenerative medicine advanced therapy designation and fast track designation to treat mild Alzheimer's disease, and orphan drug designation, fast track designation, and rare pediatric disease designation to treat hypoplastic left heart syndrome, or HLHS.
HLHS is a rare pediatric disease.
Longeveron shares were down 5.6% in recent trading.
Price: 1.58, Change: -0.09, Percent Change: -5.57
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.